AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaXis and therapy in light of the omicron variants

Giesen N, Busch E, Schalk E, Beutel G, Ruethrich MM, Hentrich M, Hertenstein B, Hirsch HH, Karthaus M, Khodamoradi Y, Koehler P, Kruger W, Koldehoff M, Krause R, Mellinghoff SC, Penack O, Sandherr M, Seggewiss-Bernhardt R, Spiekermanny K, Sprute R, Stemler J, Weissinger F, Woermann B, Wolf HH, Cornely OA, Rieger CT, Von Lilienfeld-Toal M (2023)

Publication Type: Journal article

Publication year: 2023

Journal

Book Volume: 181

Pages Range: 102-118

DOI: 10.1016/j.ejca.2022.11.030

Abstract

The novel coronavirus SARS-CoV-2 , the associated infectious disease COVID-19 pose a significant challenge to healthcare systems worldwide. Patients with cancer have been identified as a high-risk population for severe infections, rendering prophylaxis and treat-ment strategies for these patients particularly important. Rapidly evolving clinical research, resulting in the recent advent of various vaccines and therapeutic agents against COVID-19, offers new options to improve care and protection of cancer patients. However, ongoing epidemiological changes and rise of new virus variants require repeated revisions and adapta-tions of prophylaxis and treatment strategies to meet these new challenges. Therefore, this guideline provides an update on evidence-based recommendations with regard to vaccination, pharmacological prophylaxis and treatment of COVID-19 in cancer patients in light of the currently dominant omicron variants. It was developed by an expert panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) based on a critical review of the most recent available data. 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Additional Organisation(s)

Involved external institutions

Robert-Bosch-Krankenhaus Germany (DE) Universitätsklinikum Heidelberg Germany (DE) Otto-von-Guericke-Universität Magdeburg Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE) Vivantes - Netzwerk für Gesundheit GmbH Germany (DE) Rotkreuzklinikum München Germany (DE) Klinikverbund Bremen (Gesundheit Nord) Germany (DE) Universität Basel Switzerland (CH) Klinikum Neuperlach Germany (DE) Goethe-Universität Frankfurt am Main Germany (DE) Universitätsmedizin Greifswald / Universitätsklinikum Greifswald Germany (DE) Universität Duisburg-Essen (UDE) Germany (DE) Deutsches Zentrum für Infektionsforschung (DZIF) Germany (DE) Charité - Universitätsmedizin Berlin Germany (DE) Sozialstiftung Bamberg Germany (DE) Ludwig-Maximilians-Universität (LMU) Germany (DE) Evangelisches Klinikum Bethel Germany (DE) Südharz Klinikum Nordhausen gGmbH Germany (DE) Universitätsklinikum Jena Germany (DE)

How to cite

APA:

Giesen, N., Busch, E., Schalk, E., Beutel, G., Ruethrich, M.M., Hentrich, M.,... Von Lilienfeld-Toal, M. (2023). AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaXis and therapy in light of the omicron variants. European Journal of Cancer, 181, 102-118. https://dx.doi.org/10.1016/j.ejca.2022.11.030

MLA:

Giesen, Nicola, et al. "AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaXis and therapy in light of the omicron variants." European Journal of Cancer 181 (2023): 102-118.

BibTeX: Download